{
    "nct_id": "NCT03520660",
    "official_title": "Long-Term Follow-Up Of Subjects With CHC Who Achieved A Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents",
    "inclusion_criteria": "* INCLUSION CRITERIA:\n\nPhase I Treatment\n\n* Male or female >= 18 years of age\n* Either treatment naive or experienced defined as failure of a prior course of interferon-based and ribavirin, DAA plus interferon and DAA only\n* Confirmation of chronic HCV infection documented by:\n\n  * A positive HCV RNA or positive HCV genotyping test at least 6-months prior to the Baseline/Day 1 visit\n  * A liver biopsy performed prior to screening visit showing evidence of chronic hepatitis.\n* Subjects must have the following laboratory parameters at screening:\n\n  * ALT <= 10 x the upper limit of normal (ULN)\n  * AST <= 10 x ULN\n  * Total bilirubin <2.5 mg/dL, Direct bilirubin <= 1.5 ULN\n  * Platelets >= 50,000 K/mm^3\n  * HbA1c <= 8.5%\n  * Hemoglobin >= 10g/dL\n  * Albumin >= 3g/dL\n  * INR <= 1.5 unless subject has known hemophilia or is stable on an anticoagulant regimen affecting INR.\n  * HCV RNA positive at screening.\n* Subjects must be of generally good health, with the exception of chronic HCV infection, as determined by the Investigator.\n\nPhase II Follow-up\n\n* Male or female >= 18 years of age.\n* SVR24 following therapy with a direct acting antiviral agent regimen and available liver biopsy performed prior to treatment.\n* Subject must be of generally good health as determined by the Investigator.\n\nEXCLUSION CRITERIA:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\nPhase I Treatment\n\n* Pregnancy or lactation\n* Inability to practice one form of adequate contraction for females of childbearing potential\n* Prior treatment with a NS5a agent\n* Current or prior history of any of the following:\n\n  * Clinically significant illness (other than HCV) or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol; subjects currently under evaluation for a potentially clinically significant illness (other than HCV) are also excluded\n  * Gastrointestinal disorder or post-operative condition that could interfere with the absorption of the study drug\n  * Decompensated liver disease as defined by serum bilirubin >= 2.5 mg/dL (with direct bilirubin >= 1.5 mg/dL), INR >1.5 a serum albumin of less than 3 g/dL, or a history of ascites, hepatorenal syndrome, variceal bleeding, or hepatic encephalopathy\n  * Solid organ transplantation\n  * Significant pulmonary disease, significant cardiac disease\n* History of malignancy or treatment for a malignancy within the past 3 years that is associated with a life expectancy <5 years (except adequately treated carcinoma in situ or basal cell carcinoma of the skin).\n* Chronic liver disease of a non-HCV etiology with the exception of steatosis (e.g., chronic hepatitis B, hemochromatosis, Wilson s disease, alfa-1 antitrypsin deficiency, cholangitis).\n* Evidence of harmful or hazardous drinking as defined as a score >= 8 on the AUDIT questionnaire.\n* Co-infection with HIV defined as the presence of anti-HIV in serum.\n* Clinically relevant drug abuse based on patient history within 12 months of screening.\n* Use of medications contraindicated with use of sofosbuvir/velpatasvir within 21 days of the Baseline/Day 1 visit; this washout period does not apply to proton pump inhibitors, which can be taken up to 7 days before baseline Day 1 for the following:\n\n  * Acid reducing Agents\n  * Antiarrhythmics\n  * Anticancer\n  * Antimycobacterial\n  * HIV antivirals\n  * Herbal supplements\n  * HMG-CoA Reductase Inhibitors\n* Use of antiviral medications within the last 30 days.\n* Chronic use of systemically administered immunosuppressive agents (e.g., prednisone equivalent >= 10 mg/day).\n* Known hypersensitivity to sofosbuvir and velpatasvir, or formulation excipients.\n* Hepatocellular carcinoma, or the presence of a mass on imaging studies of the liver that is suggestive of hepatocellular carcinoma, or an alpha-fetoprotein level of greater than 500 mg/mL\n* Active psychiatric problems such as major depression, schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or personality disorder that, in the investigator s opinion, might interfere with participation in the study.\n* Presence of conditions that, in the opinion of the investigators, would not allow the subject to n the current study for at least 1 year.\n\nPhase II Follow-up\n\n* Pregnancy\n* Current or prior history of any of the following:\n\n  * Clinically significant illness (other than resolved HCV) or any other major medical disorder that may interfere with subject treatment, assessment, or compliance with the protocol; subjects currently under evaluation for a potentially clinically significant illness\n\n(other than HCV) are also excluded\n\n--Decompensated liver disease as defined by serum bilirubin >= 2.5 mg/dL (with direct\n\nbilirubin >= 1.5 mg/dL), INR >1.5 a serum albumin of less than 3 g/dL, or a history of ascites, hepatorenal syndrome, variceal bleeding, or hepatic encephalopathy.\n\n* Solid organ transplantation\n* Significant pulmonary disease, significant cardiac disease\n\n  * History of malignancy or treatment for a malignancy within the past 3 years that is associated with a life expectancy <5 years (except adequately treated carcinoma in situ or basal cell carcinoma of the skin)\n  * Chronic liver disease with the exception of steatosis (e.g., chronic hepatitis B, hemochromatosis, Wilson s disease, alfa-1 antitrypsin deficiency, cholangitis)\n  * Evidence of harmful or hazardous drinking as defined as a score >= 8 on the AUDIT questionnaire\n  * Co-infection with HIV defined as the presence of anti-HIV in serum\n  * Clinically relevant drug abuse based on patient history within 12 months of screening\n  * Chronic use of systemically administered immunosuppressive agents (e.g., prednisone equivalent >= 10 mg/day)\n  * Hepatocellular carcinoma, or the presence of a mass on imaging studies of the liver that is suggestive of hepatocellular carcinoma, or an alpha-fetoprotein level of greater than 500 mg/mL\n  * Active psychiatric problems such as major depression, schizophrenia, bipolar illness, obsessive-compulsive disorder, severe anxiety, or personality disorder that, in the investigator s opinion, might interfere with participation in the study\n  * Presence of conditions that, in the opinion of the investigators, would not allow the patient to be followed in the current study for at least 1 year.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}